Immuno-oncology company Calidi Biotherapeutics Inc said on Tuesday that it has completed Series A investments with two South Korean firms Won & Partners and Greentable Co Ltd.
This financing was led by Heehyoung Lee, PhD, co-founder and managing partner of LumeBio, advisor to Calidi Biotherapeutics and a veteran in the biopharmaceutical space.
The Series A investments will be used by Calidi to advance manufacturing in preparation for its pre-IND and IND filings. It is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.
Previously, Dr Lee has held positions at Hanmi Pharmaceuticals, Sorrento Therapeutics and City of Hope.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886